Non-Melanoma Skin Cancer Aggravation in Polycythemia Vera: Triggered by Ruxolitinib and Silenced With an IFN/Cemiplimab
Keywords:
cutaneous squamous cell carcinoma, Ruxolitinib, anti-PD-1, interferon alpha2bReferences
Lin JQ, Li SQ, Li S, et al. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis. J Am Acad Dermatol. 2022;86(2):339-344. DOI:10.1016/j.jaad.2021.10.004.Lin JQ, Li SQ, Li S, et al. A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis. J Am Acad Dermatol. 202;86(2):339-344. DOI: 10.1016/j.jaad.2021.10.004.. PMID: 34648874.
Razaghi A, Razaghi A, Durand-Dubief M, Brusselaers N, Björnstedt M. Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy. Front Immunol. 2023;14:1249330. DOI: 10.3389/fimmu.2023.1249330. PMID: 37691915. PMCID: PMC10484344.Durand-Dubief M, Brusselaers N, Björnstedt M. Combining PD-1/PD-L1 blockade with type I interferon in cancer therapy. Front Immunol. 2023;14:1249330. Published 2023 Aug 24. DOI:10.3389/fimmu.2023.1249330
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Efterpi Zafiriou, Emmanouil Karampinis, Vasileios Papadopoulos, Georgia Stefani, Athanasios Kotsakis, George Vassilopoulos

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.